Storyline
Sanofi pays $180 million for rights to Kali Therapeutics' phase 1 trispecific antibody
Sanofi has re-entered the T-cell engager space by securing rights to a phase 1-stage trispecific antibody from Kali Therapeutics.
Evidence locked
Today's free sample is only available for the edition's flagship storyline.
Evidence preview
- Sanofi pays $180m for rights to Kali autoimmune drug - pharmaphorumpharmaphorum.com
- Sanofi returns to T-cell engager territory with $180M deal for Kali trispecific...fiercebiotech.com